3 New Strong Buy Ratings from Top-Rated Analysts: 06/26/2026

Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:

• Pacs Group (PACS) — Healthcare services play earns unanimous Wall Street backing.
• Ani Pharmaceuticals (ANIP) — Rare disease leader eyes 50% upside ahead.
• Beone Medicines (ONC) — Top mid-cap oncology pick targets 60% upside.

P.S. Want a bonus pick every week? Join our weekly Live training at 7pm every Monday to access our Editor-in-Chief’s Trade of the Week. Sign up for the next one here (completely complimentary!)

1. Pacs Group (NYSE: PACS)

Unanimous bullish consensus from Wall Street is a rare thing — and PACS Group has it. The company provides services in the medical care industry, operating as a relatively new public company since April 2024 but already establishing strong market positioning, capitalizing on structural trends in healthcare services delivery.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $38.90 — get current quote

Max 1-year forecast: $52.00

Why we're watching:

• Analyst support: PACS enjoys perfect bullish consensus from Wall Street with 4 analysts covering the stock. See the recommendations
• Truist Securities' David S Macdonald (a top 8% rated analyst) recently raised his price target to $52 (over 30% implied upside!) following Q1 2026 earnings, attributing the increase to the quarter's strong results and management's updated FY 2026 guidance.
• In his analyst commentary, MacDonald noted management's optimism about future earnings following a quarter where the company reported Q1 EPS of $1.56 with full-year guidance of $2.26, suggesting robust earnings acceleration ahead.
• Industry ranking context: Pacs Group is currently the 4th highest-rated stock in the Medical Care Facility industry, which has an Industry Rating of A, positioning the company in a high-quality sector with strong fundamentals.
• Zen Rating highlights: PACS earns an overall A from our Zen Ratings, which amounts to a Strong Buy recommendation. This grade doesn’t come lightly — it means that PACS passed our 115-factor fundamental review with flying colors. 
• Component Grades: The company demonstrates solid fundamental strength with Momentum earning a B grade, Safety also at B, and Sentiment leading with an A grade, while Financials receive a C reflecting the company's earlier stage of public market operations. See all 7 Component Grades here

2. Ani Pharmaceuticals (NASDAQ: ANIP)

Cortrophin Gel is fueling a quiet transformation at ANI Pharmaceuticals. The biopharmaceutical company concentrates on the development, production, and commercialization of both proprietary branded and generic pharmaceutical products — and the company is now driving growth through its rare disease franchise, with Cortrophin Gel leading the charge in 2026.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $82.72 — get current quote

Max 1-year forecast: $124.00

Why we're watching:

• Analyst support: While coverage is very slim with just 1 recommendation at present, it’s bullish: ANIP receives a Strong Buy recommendation with a compelling $124 price target representing 50% upside potential from current levels. See forecast updates here
• That’s from Guggenheim researcher Vamil Divan (a top 4% rated analyst), who maintains his Strong Buy rating with a $124 price target, reflecting confidence in the company's rare disease strategy and Cortrophin Gel's commercial trajectory.
• The stock trades at an attractive valuation of just 9.8x forward earnings despite strong growth prospects, with analysts projecting EPS growth of 134% in the coming year driven by the rare disease portfolio expansion.
• Industry ranking context: ANI Pharmaceuticals is currently the 3rd highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of B, demonstrating strong relative positioning in a quality sector.
• Zen Rating highlights: ANIP earns an overall Strong Buy recommendation from the Zen Ratings, with a grade of A. Only the top 5% of stocks tracked are in this tier! 
• Component Grades: The company shows balanced strength with Value earning an A grade, Sentiment and Financials both receiving B grades, reflecting positive analyst and market perception of the company's strategic direction. See all 7 Component Grades here

3. Beone Medicines (NASDAQ: ONC)

A global oncology powerhouse is quietly building one of biotech's most impressive pipelines. BeOne Medicines (formerly BeiGene) stands as a prominent global oncology enterprise committed to identifying, advancing, and commercializing cutting-edge cancer therapies — with its foundational hematology franchise anchored by BRUKINSA, the best-in-class BTK inhibitor driving sustained growth, while an impressive solid tumor pipeline creates multiple catalysts ahead.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $277.12— get current quote

Max 1-year forecast: $436.00

Why we're watching:

• Analyst support: ONC enjoys broad Wall Street backing with a Strong Buy consensus among the 7 analysts covering the stock. See the recommendations here
• Guggenheim's Michael Schmidt (a top 2% rated analyst) recently raised his price target to $420 (over 50% upside) following Q1 earnings, calling ONC Guggenheim's "Top Mid-Cap Pick" and citing the quarter's revenue beat and FY 2026 guidance raise.
• In detailed analyst commentary, Schmidt highlighted that "BRUKINSA has firmly established itself as the foundational, best-in-class BTK inhibitor with unmatched long-term efficacy and safety data" with Q1 revenue of $1.51B and updated full-year guidance of $6.3B to $6.5B.  
• Industry ranking context: BeOne Medicines is currently the 13th highest-rated stock out of over 400 in the Biotech industry. 
• Zen Rating highlights: ONC passed our 115-factor fundamental review with great scores — earning it a spot in the top tier of stocks we track, an A rating or Strong Buy recommendation.
• Component Grades: The stock shows solid balanced strength across metrics with Growth and Financials both earning B grades, Value at B, and AI capabilities also rated B, reflecting the company's innovative pipeline and commercial execution. See all 7 Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.